New Jersey S 2035: Requires public members of Drug Utilization Review Board to disclose financial interests and benefits received from and investment interests held in pharmaceutical distributors, pharmaceutical manufacturers, or pharmacy benefits managers.*

Status: Substituted by A277 (1R) (as of 2021-06-03)

State: New Jersey · Session: 219 · Bill: S 2035

Subjects: PHARMACEUTIC

Sponsors: Singleton, Troy, Turner, Shirley K.

View New Jersey S 2035 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.